Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.54 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343669 | 1.00 | PTGS2 (0.54) | PTGS2PTGS1AKR1C3CXCR2CXCR1 | |
| SCHEMBL13604937 | 0.81 | PTGS2 (0.50) | PTGS2PTGS1AKR1C3CXCR2CXCR1 | |
| SCHEMBL16413957 | 0.76 | PTGS2 (0.59) | PTGS2PTGS1AKR1C3CXCR2CXCR1 | |
| SCHEMBL1345594 | 0.75 | PTGS2 (0.54) | PTGS2PTGS1AKR1C3CXCR2CXCR1 | |
| SCHEMBL1345639 | 0.75 | PTGS2 (0.54) | PTGS2PTGS1AKR1C3CXCR2CXCR1 | |
| SCHEMBL16434147 | 0.75 | CA2 (0.48) | PTGS1LMNANFKB1TSHRBLM | |
| SCHEMBL7622372 | 0.74 | PTGS2 (0.67) | PTGS2PTGS1AKR1C3CXCR2CXCR1 | |
| SCHEMBL10825029 | 0.74 | PTGS2 (0.67) | PTGS2PTGS1AKR1C3CXCR2CXCR1 | |
| SCHEMBL245190 | 0.74 | CXCR2 (0.69) | PTGS2PTGS1AKR1C3CXCR2CXCR1 | |
| SCHEMBL1345636 | 0.74 | CXCR2 (0.69) | PTGS2PTGS1AKR1C3CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | claimed |
| EP-1455773-B1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-04 | — | — | EP | claimed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | claimed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | claimed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | claimed |
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| EP-2229942-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-1455773-B1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-04 | — | — | EP | disclosed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | disclosed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | CXCR2, FPR1, CCR2 | PTGS2 99/4885PTGS1 88/4885AKR1C3 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.